Juhi Juneja

Title: Juhi Juneja: Innovator in Serum Albumin Binding Technologies

Introduction

Juhi Juneja is a prominent inventor based in Lexington, MA (US). She has made significant contributions to the field of biochemistry, particularly in the development of polypeptides that bind to serum albumin. With a total of 2 patents, her work is paving the way for advancements in diagnostic and therapeutic applications.

Latest Patents

Juhi's latest patents include innovative polypeptides that feature tenth fibronectin type III domains (Fn3) capable of binding to serum albumin. These polypeptides are designed to enhance the efficacy of fusion molecules, which combine serum albumin binding Fn3 with heterologous proteins. This technology holds promise for various diagnostic and therapeutic applications, showcasing her expertise in the field.

Career Highlights

Juhi Juneja is currently employed at Bristol-Myers Squibb Company, where she continues to push the boundaries of scientific research. Her work is characterized by a commitment to innovation and excellence, contributing to the company's mission of improving patient outcomes through advanced therapies.

Collaborations

Throughout her career, Juhi has collaborated with notable colleagues, including Stanley Richard Krystek, Jr. and Tracy S. Mitchell. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Juhi Juneja's contributions to serum albumin binding technologies exemplify her dedication to innovation in the field of biochemistry. Her patents and ongoing work at Bristol-Myers Squibb Company are set to make a lasting impact on diagnostic and therapeutic applications.